Add-On Cyclic Angiotensin-(1-7) with Cyclophosphamide Arrests Progressive Kidney Disease in Rats with ANCA Associated Glomerulonephritis

Rapidly progressive crescentic glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies (ANCA-GN) is a major cause of renal failure. Current immunosuppressive therapies are associated with severe side effects, intensifying the need for new therapeutic strategies. The activation of Mas receptor/Angiotensin-(1-7) axis exerted renoprotection in chronic kidney disease. Here, we investigated the effect of adding the lanthionine-stabilized cyclic form of angiotensin-1-7 [cAng-(1-7)] to cyclophosphamide in a rat model of ANCA-GN. At the onset of proteinuria, Wistar Kyoto rats with ANCA-GN received vehicle or a single bolus of cyclophosphamide, with or without daily cAng-(1-7). Treatment with cAng-(1-7) plus cyclophosphamide reduced proteinuria by 85% vs. vehicle, and by 60% vs. cyclophosphamide, and dramatically limited glomerular crescents to less than 10%. The addition of cAng-(1-7) to cyclophosphamide protected against glomerular inflammation and endothelial rarefaction and restored the normal distribution of parietal epithelial cells. Ultrastructural analysis revealed a preserved GBM, glomerular endothelium and podocyte structure, demonstrating that combination therapy provided an additional layer of renoprotection. This study demonstrates that adding cAng-(1-7) to a partially effective dose of cyclophosphamide arrests the progression of renal disease in rats with ANCA-GN, suggesting that cAng-(1-7) could be a novel clinical approach for sparing immunosuppressants.

[1]  L. Truong,et al.  Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: implications to predisposing to COVID-19 kidney complications , 2021, Kidney International.

[2]  H. Trimarchi Crescents in primary glomerulonephritis: a pattern of injury with dissimilar actors. A pathophysiologic perspective , 2021, Pediatric Nephrology.

[3]  G. Remuzzi,et al.  Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis , 2021, Nephron.

[4]  H. Kono,et al.  Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis , 2021, Journal of translational autoimmunity.

[5]  H. Choi,et al.  Angiotensin-[1–7] attenuates kidney injury in experimental Alport syndrome , 2020, Scientific Reports.

[6]  H. Anders,et al.  The glomerular crescent: triggers, evolution, resolution, and implications for therapy , 2020, Current opinion in nephrology and hypertension.

[7]  P. Merkel,et al.  ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.

[8]  G. Remuzzi,et al.  Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. , 2019, Kidney international.

[9]  M. Teixeira,et al.  Angiotensin-(1-7) and Alamandine Promote Anti-inflammatory Response in Macrophages In Vitro and In Vivo , 2019, Mediators of inflammation.

[10]  G. Moll,et al.  Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models , 2019, Peptides.

[11]  J. Niles,et al.  Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2018, Rheumatic diseases clinics of North America.

[12]  D. Nikolic-Paterson,et al.  An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis , 2018, International journal of immunopathology and pharmacology.

[13]  D. Nikolic-Paterson,et al.  Matrix metalloproteinase‐12 deficiency attenuates experimental crescentic anti‐glomerular basement membrane glomerulonephritis , 2016, Nephrology.

[14]  M. Teixeira,et al.  Angiotensin-(1-7) Promotes Resolution of Neutrophilic Inflammation in a Model of Antigen-Induced Arthritis in Mice , 2017, Front. Immunol..

[15]  G. Remuzzi,et al.  The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. , 2017, The American journal of pathology.

[16]  J. C. Jennette,et al.  ANCA Glomerulonephritis and Vasculitis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[17]  J. Winkler,et al.  Role of the receptor Mas in macrophage-mediated inflammation in vivo , 2016, Proceedings of the National Academy of Sciences.

[18]  G. Remuzzi,et al.  Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. , 2016, Pharmacological research.

[19]  G. Remuzzi,et al.  Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. , 2016, Journal of the American Society of Nephrology.

[20]  Lei Zhao,et al.  M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[21]  S. Nishio,et al.  Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. , 2014, Journal of the American Society of Nephrology : JASN.

[22]  J. Scholey,et al.  Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. , 2014, American journal of physiology. Renal physiology.

[23]  N. Perico,et al.  Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. , 2013, The American journal of pathology.

[24]  M. Teixeira,et al.  ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis , 2013, British journal of pharmacology.

[25]  C. Manthey,et al.  Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. , 2013, American journal of physiology. Renal physiology.

[26]  L. P. de Sousa,et al.  Anti-Inflammatory Effects of the Activation of the Angiotensin-(1–7) Receptor, Mas, in Experimental Models of Arthritis , 2010, The Journal of Immunology.

[27]  W. Border,et al.  Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. , 2010, American journal of physiology. Renal physiology.

[28]  T. Walther,et al.  Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog , 2009, Journal of Pharmacology and Experimental Therapeutics.

[29]  Y. Sado,et al.  Podocytes contribute to the formation of glomerular crescents. , 2008, Journal of the American Society of Nephrology : JASN.

[30]  M. Hickey,et al.  Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. , 2006, Journal of the American Society of Nephrology : JASN.

[31]  N. Perico,et al.  The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. , 2005, Kidney international. Supplement.

[32]  David Andreu,et al.  The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[33]  P. Heeringa,et al.  The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. , 2005, The American journal of pathology.

[34]  J. Jennette Rapidly progressive crescentic glomerulonephritis. , 2003, Kidney international.

[35]  C. Svensson,et al.  Synthesis and biological activities of cyclic lanthionine enkephalin analogues : δ-opioid receptor selective ligands , 2002 .

[36]  P. Patston,et al.  Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. , 2002, Archives of biochemistry and biophysics.

[37]  D. Ganten,et al.  Converting enzyme determines plasma clearance of angiotensin-(1-7). , 1998, Hypertension.

[38]  J. Nishiyama,et al.  Acute glomerulonephritis. , 2000, Internal medicine.

[39]  M. Wigler,et al.  Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. Dzau,et al.  Human neutrophils release serine proteases capable of activating prorenin. , 1987, Circulation research.